Hyloris Lines Up Hectic Year Of Clinical Trials And Major US Launch
Value-Added Medicines Developer Quietly Reframes 30-Asset Goal
Hyloris has an eventful year ahead as it plans to conduct numerous trials for products in its ever-expanding pipeline and launch Maxigesic IV in the US.
You may also be interested in...
Hyloris has received US approval for its generic podofilox gel, previously referred to as HY-016.
Hyloris has submitted additional data to the US Food and Drug Administration about its value-added analgesic Maxigesic IV, following enquiries about potential extractable and leachable compounds expected to be present in the product due to the packaging.
Hyloris Pharmaceuticals’ new idiopathic rhinitis treatment sets it on track to achieve its target of around 30 portfolio assets by the end of 2024.